$ cat ./records/gates-foundation-commits-40-million-to-diarrheal-disease-vaccine--2014.txt
Gates Foundation Commits $40 Million to Diarrheal Disease Vaccine Development
[RECORD.TXT] · cat --full
The Gates Foundation committed $40 million to vaccine research targeting the leading diarrheal disease killers — cholera and Shigella — which together cause hundreds of thousands of child deaths annually in low-income countries. The investment addressed a critical gap: annual global cholera vaccine manufacturing capacity at the time was roughly 4 million doses against estimated demand exceeding 20 million doses. Funding supported development of oral cholera vaccines and the Shigella conjugate vaccine programme that reached Phase III trials by the early 2020s.
Source: https://www.gatesfoundation.org/our-work/programs/global-health/enteric-and-diarrheal-diseases
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Commits $50 Million to West Africa Ebola Emergency Response
Next →
Gates Foundation granted to Grantmakers Concerned with Immigrants and Refugees for DACA implementation support
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.